Amplyx Pharmaceuticals Raises $67m in Series C Financing

Amplyx Pharmaceuticals, a San Diego, CA-based company developing novel antifungal agents for life-threatening fungal infections, raised $67m in Series C financing.

The round was led by Sofinnova Venture Partners with participation from other new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital and existing investors New Enterprise Associates, RiverVest Venture Partners, 3×5 RiverVest II and BioMed Ventures. In conjunction with the financing, Anand Mehra, M.D., managing partner at Sofinnova Ventures, and Johan K├Ârdel, Ph.D., senior partner at Lundbeckfonden Ventures, will join Amplyx’ board of directors.

Led by Ciara Kennedy, Ph.D., chief executive officer, Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections.
The company, which has raised $118.5m in venture capital and secured more than $10m in grants from the National Institutes of Health, will use the proceeds to advance the clinical development of APX001, its broad-spectrum antifungal agent, to treat life threatening fungal infections. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive aspergillosis and invasive candidiasis planned for initiation later this year.



Join the discussion